Alternative titles; symbols
HGNC Approved Gene Symbol: TEAD3
Cytogenetic location: 6p21.31 Genomic coordinates (GRCh38): 6:35,473,597-35,497,079 (from NCBI)
Transcriptional enhancer factors (TEFs), a family of transcription factors, contain the TEA/ATTS DNA-binding domain. See TEF1 (TEAD1; 189967).
Jacquemin et al. (1997) noted that putative TEF-binding sites had been identified in the placenta-specific human chorionic somatomammotropin B gene (CSH2; 118820) enhancer. To isolate TEFs expressed in placenta, Jacquemin et al. (1997) used degenerate oligonucleotides corresponding to conserved regions of the TEA/ATTS domain for PCR amplification of a human placental cDNA library. They used the resulting PCR fragment to clone a full-length TEF5 cDNA. The predicted 435-amino acid protein shares 79%, 83%, and 84% sequence similarity with TEF4 (TEAD2; 601729), TEF3 (TEAD4; 601714), and TEF1, respectively. Northern blot analysis showed that TEF5 is expressed as a 3.2-kb mRNA in human placenta and skeletal muscle, and more weakly in heart; an additional 8.1-kb mRNA was present in placenta and a 1.7-kb transcript in skeletal muscle.
Jacquemin et al. (1997) demonstrated that TEF5 binds to multiple functional sites in the CSH2 enhancer. Mutations in these sites that disrupted TEF5 binding also inactivated the transcription-enhancing activity of the element. The authors showed that the placental protein f/chorionic somatomammotropin enhancer factor-1 (PPf/CSEF1), which binds to TEF-binding sites in the CSH2 enhancer, is a proteolytic degradation product of TEFs. They suggested that TEF5 regulates the activity of the CSH2 gene enhancer and is an important regulatory factor in the human placenta.
Jiang et al. (1999) noted that human chorionic somatomammotropin (see 150200) gene expression in the placenta is controlled by an enhancer (designated CSEn) containing SV40-related GT-IIC and SphI/SphII enhansons (see 189967). TEF5, whose mRNA is abundant in placenta, was shown to bind cooperatively to a unique, tandemly repeated element in CSEn2, suggesting that TEF5 regulates CSEn activity. The open reading frame of one 3,033-bp clone was identical to TEF5 and contained 300- and 1423-bp 5-prime and 3-prime-untranslated regions, respectively. The in vitro generated approximately 53-kD TEF5 polypeptide binds specifically to GT-IIC and SphI/SphII oligonucleotides. Overexpression of TEF5 in BeWo cells using the intact 3,033-bp cDNA transactivates the chorionic somatomammotropin and SV40 enhancers and artificial enhancers composed of tandemly repeated GT-IIc enhansons, but not control octomeric enhansons. The authors concluded that TEF5 is a transactivator that is likely involved in the transactivation of CSEn function.
By fluorescence in situ hybridization and radiation hybrid analysis, Jacquemin et al. (1999) mapped the TEAD3 gene to 6p21.2. By interspecific backcross analysis, Jacquemin et al. (1999) mapped the mouse Tead3 gene to the proximal region of chromosome 17.
Jacquemin, P., Chen, Z., Martial, J. A., Davidson, I. Genomic structure and chromosomal mapping of the mouse transcription factor TEF-5 (Tead3) gene. Mammalian Genome 10: 632-634, 1999. [PubMed: 10341100] [Full Text: https://doi.org/10.1007/s003359901059]
Jacquemin, P., Depetris, D., Mattei, M.-G., Martial, J. A., Davidson, I. Localization of human transcription factor TEF-4 and TEF-5 (TEAD2, TEAD3) genes to chromosomes 19q13.3 and 6p21.2 using fluorescence in situ hybridization and radiation hybrid analysis. Genomics 55: 127-129, 1999. [PubMed: 9889009] [Full Text: https://doi.org/10.1006/geno.1998.5628]
Jacquemin, P., Martial, J. A., Davidson, I. Human TEF-5 is preferentially expressed in placenta and binds to multiple functional elements of the human chorionic somatomammotropin-B gene enhancer. J. Biol. Chem. 272: 12928-12937, 1997. [PubMed: 9148898] [Full Text: https://doi.org/10.1074/jbc.272.20.12928]
Jiang, S.-W., Wu, K., Eberhardt, N. L. Human placental TEF-5 transactivates the human chorionic somatomammotropin gene enhancer. Molec. Endocr. 13: 879-889, 1999. [PubMed: 10379887] [Full Text: https://doi.org/10.1210/mend.13.6.0288]